Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.

Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X, Zhang J, Kochel CM, Choi W, McConkey DJ, Drake CG, Bivalacqua TJ.

Eur Urol Oncol. 2019 Feb 26. pii: S2588-9311(19)30025-2. doi: 10.1016/j.euo.2019.01.017. [Epub ahead of print]

PMID:
31411999
2.

Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.

Eich ML, Chaux A, Guner G, Taheri D, Mendoza Rodriguez MA, Rodriguez Peña MDC, Baras AS, Hahn NM, Drake C, Sharma R, Bivalacqua TJ, Rezaei K, Netto GJ.

Hum Pathol. 2019 Jul;89:24-32. doi: 10.1016/j.humpath.2019.04.003. Epub 2019 Apr 24.

PMID:
31026471
3.

Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.

Marshall CH, Fu W, Wang H, Baras AS, Lotan TL, Antonarakis ES.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):59-65. doi: 10.1038/s41391-018-0086-1. Epub 2018 Aug 31.

4.

miRge 2.0 for comprehensive analysis of microRNA sequencing data.

Lu Y, Baras AS, Halushka MK.

BMC Bioinformatics. 2018 Jul 23;19(1):275. doi: 10.1186/s12859-018-2287-y.

5.

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity.

Danilova L, Anagnostou V, Caushi JX, Sidhom JW, Guo H, Chan HY, Suri P, Tam A, Zhang J, Asmar ME, Marrone KA, Naidoo J, Brahmer JR, Forde PM, Baras AS, Cope L, Velculescu VE, Pardoll DM, Housseau F, Smith KN.

Cancer Immunol Res. 2018 Aug;6(8):888-899. doi: 10.1158/2326-6066.CIR-18-0129. Epub 2018 Jun 12.

6.

Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling.

Baras AS, Naidoo J, Hann CL, Illei PB, Reninger CW, Lauring J.

J Natl Compr Canc Netw. 2018 May;16(5):467-472. doi: 10.6004/jnccn.2017.7203.

PMID:
29752320
7.

Implications of the tumor immune microenvironment for staging and therapeutics.

Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A.

Mod Pathol. 2018 Feb;31(2):214-234. doi: 10.1038/modpathol.2017.156. Epub 2017 Dec 1. Review.

8.

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.

Kashiwagi E, Inoue S, Mizushima T, Chen J, Ide H, Kawahara T, Reis LO, Baras AS, Netto GJ, Miyamoto H.

Br J Cancer. 2018 Jan;118(2):213-223. doi: 10.1038/bjc.2017.393. Epub 2017 Nov 9.

9.

Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma.

Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, Gorin MA.

Ann Nucl Med. 2018 Jan;32(1):69-74. doi: 10.1007/s12149-017-1216-x. Epub 2017 Oct 24.

10.

Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression.

Rowe SP, Gorin MA, Solnes LB, Ball MW, Choudhary A, Pierorazio PM, Epstein JI, Javadi MS, Allaf ME, Baras AS.

EJNMMI Res. 2017 Oct 2;7(1):80. doi: 10.1186/s13550-017-0329-5.

11.

Toward the human cellular microRNAome.

McCall MN, Kim MS, Adil M, Patil AH, Lu Y, Mitchell CJ, Leal-Rojas P, Xu J, Kumar M, Dawson VL, Dawson TM, Baras AS, Rosenberg AZ, Arking DE, Burns KH, Pandey A, Halushka MK.

Genome Res. 2017 Oct;27(10):1769-1781. doi: 10.1101/gr.222067.117. Epub 2017 Sep 6.

12.

Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, Netto GJ, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG, Bivalacqua TJ.

Cancer Immunol Res. 2017 Jul;5(7):594-603. doi: 10.1158/2326-6066.CIR-16-0267. Epub 2017 Jun 6.

13.

Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal Masses.

Sheikhbahaei S, Jones CS, Porter KK, Rowe SP, Gorin MA, Baras AS, Pierorazio PM, Ball MW, Higuchi T, Johnson PT, Solnes LB, Epstein JI, Allaf ME, Javadi MS.

Clin Nucl Med. 2017 Apr;42(4):e188-e193. doi: 10.1097/RLU.0000000000001534.

PMID:
28114223
14.

Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer.

Chappidi MR, Kates M, Brant A, Baras AS, Netto GJ, Pierorazio PM, Hahn NM, Bivalacqua TJ.

Urology. 2017 Apr;102:148-158. doi: 10.1016/j.urology.2016.10.064. Epub 2017 Jan 16.

15.

The effect of limited (tertiary) Gleason pattern 5 on the new prostate cancer grade groups.

Baras AS, Nelson JB, Han M, Parwani AV, Epstein JI.

Hum Pathol. 2017 May;63:27-32. doi: 10.1016/j.humpath.2016.12.008. Epub 2016 Dec 16.

PMID:
27993581
16.

Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?

Brant A, Kates M, Chappidi MR, Patel HD, Sopko NA, Netto GJ, Baras AS, Hahn NM, Pierorazio PM, Bivalacqua TJ.

Urol Oncol. 2017 Jan;35(1):34.e17-34.e25. doi: 10.1016/j.urolonc.2016.08.005. Epub 2016 Sep 14.

PMID:
27639777
17.

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.

Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, Netto G, Bivalacqua TJ.

Oncoimmunology. 2016 Feb 18;5(5):e1134412. doi: 10.1080/2162402X.2015.1134412. eCollection 2016 May.

18.

Accuracy of urethral frozen section during radical cystectomy for bladder cancer.

Kates M, Ball MW, Chappidi MR, Baras AS, Gordetsky J, Sopko NA, Brant A, Pierorazio PM, Epstein JI, Schoenberg MP, Bivalacqua TJ.

Urol Oncol. 2016 Dec;34(12):532.e1-532.e6. doi: 10.1016/j.urolonc.2016.06.014. Epub 2016 Jul 16.

PMID:
27432433
19.

Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.

Kashiwagi E, Ide H, Inoue S, Kawahara T, Zheng Y, Reis LO, Baras AS, Miyamoto H.

Oncotarget. 2016 Aug 2;7(31):49169-49179. doi: 10.18632/oncotarget.9994.

20.

ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.

Morais CL, Guedes LB, Hicks J, Baras AS, De Marzo AM, Lotan TL.

Hum Pathol. 2016 Sep;55:117-25. doi: 10.1016/j.humpath.2016.04.017. Epub 2016 May 14.

21.

Cytopathologic features of clear cell papillary renal cell carcinoma: A recently described variant to be considered in the differential diagnosis of clear cell renal epithelial neoplasms.

Sayeed S, Lindsey KG, Baras AS, Jackson C, Powers CN, Uram-Tuculescu C, Smith SC.

Cancer Cytopathol. 2016 Aug;124(8):565-72. doi: 10.1002/cncy.21721. Epub 2016 Apr 7.

22.

A benchmark for microRNA quantification algorithms using the OpenArray platform.

McCall MN, Baras AS, Crits-Christoph A, Ingersoll R, McAlexander MA, Witwer KW, Halushka MK.

BMC Bioinformatics. 2016 Mar 22;17:138. doi: 10.1186/s12859-016-0987-8.

23.

Integrative discovery of CD98 as a melanoma biomarker.

Theodosakis N, Micevic G, Sharma R, Baras AS, Lazova R, Bosenberg MW, Rodić N.

Pigment Cell Melanoma Res. 2016 May;29(3):385-7. doi: 10.1111/pcmr.12464. Epub 2016 Apr 10. No abstract available.

PMID:
26850337
24.

Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.

Kawahara T, Ide H, Kashiwagi E, Patterson JD, Inoue S, Shareef HK, Aljarah AK, Zheng Y, Baras AS, Miyamoto H.

Am J Cancer Res. 2015 Sep 15;5(10):2959-68. eCollection 2015.

25.

Evolution of cellular morpho-phenotypes in cancer metastasis.

Wu PH, Phillip JM, Khatau SB, Chen WC, Stirman J, Rosseel S, Tschudi K, Van Patten J, Wong M, Gupta S, Baras AS, Leek JT, Maitra A, Wirtz D.

Sci Rep. 2015 Dec 17;5:18437. doi: 10.1038/srep18437.

26.

Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.

Baras AS, Gandhi N, Munari E, Faraj S, Shultz L, Marchionni L, Schoenberg M, Hahn N, Hoque MO, Berman D, Bivalacqua TJ, Netto G.

PLoS One. 2015 Nov 24;10(11):e0143990. doi: 10.1371/journal.pone.0143990. eCollection 2015. No abstract available.

27.

A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.

Park JC, Gandhi NM, Carducci MA, Eisenberger MA, Baras AS, Netto GJ, Liu JJ, Drake CG, Schoenberg MP, Bivalacqua TJ, Hahn NM.

J Urol. 2016 Apr;195(4 Pt 1):880-5. doi: 10.1016/j.juro.2015.11.024. Epub 2015 Nov 18.

PMID:
26598426
28.

miRge - A Multiplexed Method of Processing Small RNA-Seq Data to Determine MicroRNA Entropy.

Baras AS, Mitchell CJ, Myers JR, Gupta S, Weng LC, Ashton JM, Cornish TC, Pandey A, Halushka MK.

PLoS One. 2015 Nov 16;10(11):e0143066. doi: 10.1371/journal.pone.0143066. eCollection 2015.

29.

Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors.

Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, Pavlovich CP, Epstein JI, Javadi MS, Allaf ME.

Eur Urol. 2016 Mar;69(3):413-6. doi: 10.1016/j.eururo.2015.08.056. Epub 2015 Sep 18.

PMID:
26386607
30.

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.

Baras AS, Gandhi N, Munari E, Faraj S, Shultz L, Marchionni L, Schoenberg M, Hahn N, Hoque MO, Berman D, Bivalacqua TJ, Netto G.

PLoS One. 2015 Jul 31;10(7):e0131245. doi: 10.1371/journal.pone.0131245. eCollection 2015. Erratum in: PLoS One. 2015;10(11):e0143990. Hoque, Mohammad [corrected to Hoque, Mohammad Obaidul].

31.

A critical evaluation of microRNA biomarkers in non-neoplastic disease.

Haider BA, Baras AS, McCall MN, Hertel JA, Cornish TC, Halushka MK.

PLoS One. 2014 Feb 26;9(2):e89565. doi: 10.1371/journal.pone.0089565. eCollection 2014.

32.

Ki-67 index as an ancillary tool in the differential diagnosis of proliferative endometrial lesions with secretory change.

Gurda GT, Baras AS, Kurman RJ.

Int J Gynecol Pathol. 2014 Mar;33(2):114-9. doi: 10.1097/PGP.0000000000000092.

PMID:
24487464
33.

Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.

Smith SC, Baras AS, Owens CR, Dancik G, Theodorescu D.

Cancer Res. 2012 Jul 15;72(14):3480-91. doi: 10.1158/0008-5472.CAN-11-3966. Epub 2012 May 14.

34.

Drug development risk and the cost of capital.

Baras AI, Baras AS, Schulman KA.

Nat Rev Drug Discov. 2012 Apr 13;11(5):347-8. doi: 10.1038/nrd3722. No abstract available.

PMID:
22498751
35.

Development and characterization of xenograft model systems for adenoid cystic carcinoma.

Moskaluk CA, Baras AS, Mancuso SA, Fan H, Davidson RJ, Dirks DC, Golden WL, Frierson HF Jr.

Lab Invest. 2011 Oct;91(10):1480-90. doi: 10.1038/labinvest.2011.105. Epub 2011 Jun 27.

36.

Loss of VOPP1 overexpression in squamous carcinoma cells induces apoptosis through oxidative cellular injury.

Baras AS, Solomon A, Davidson R, Moskaluk CA.

Lab Invest. 2011 Aug;91(8):1170-80. doi: 10.1038/labinvest.2011.70. Epub 2011 Apr 25.

37.

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.

Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, Fradet Y, Lehmann J, Stöckle M, Hartmann A, Lee JK, Theodorescu D.

Lancet Oncol. 2011 Feb;12(2):137-43. doi: 10.1016/S1470-2045(10)70296-5. Epub 2011 Jan 20.

38.

Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.

Smith SC, Havaleshko DM, Moon K, Baras AS, Lee J, Bekiranov S, Burke DJ, Theodorescu D.

Neoplasia. 2011 Jan;13(1):72-80.

39.

PICquant: a quantitative platform to measure differential peptide abundance using dual-isotopic labeling with 12C6- and 13C6-phenyl isocyanate.

Lyons CE, Victor KG, Moshnikov SA, Bachmann LM, Baras AS, Dettmann KM, Cross JV, Templeton DJ.

Anal Chem. 2011 Feb 1;83(3):856-65. doi: 10.1021/ac102461e. Epub 2010 Dec 30.

40.

The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.

Smith SC, Baras AS, Lee JK, Theodorescu D.

Cancer Res. 2010 Mar 1;70(5):1753-8. doi: 10.1158/0008-5472.CAN-09-3562. Epub 2010 Feb 16. Review.

41.

Depot medroxyprogesterone acetate: a risk factor for cervical stenosis after loop electrosurgical excisional procedure management of cervical intraepithelial neoplasia?

Martirosian TE, Smith SC, Baras AS, Darracott MM.

J Low Genit Tract Dis. 2010 Jan;14(1):37-42. doi: 10.1097/LGT.0b013e3181b0f73f.

PMID:
20040834
42.

Integrative genomics identifies DSCR1 (RCAN1) as a novel NFAT-dependent mediator of phenotypic modulation in vascular smooth muscle cells.

Lee MY, Garvey SM, Baras AS, Lemmon JA, Gomez MF, Schoppee Bortz PD, Daum G, LeBoeuf RC, Wamhoff BR.

Hum Mol Genet. 2010 Feb 1;19(3):468-79. doi: 10.1093/hmg/ddp511. Epub 2009 Nov 19.

43.

Expression of ral GTPases, their effectors, and activators in human bladder cancer.

Smith SC, Oxford G, Baras AS, Owens C, Havaleshko D, Brautigan DL, Safo MK, Theodorescu D.

Clin Cancer Res. 2007 Jul 1;13(13):3803-13.

44.

Concurrent loss of heterozygosity and copy number analysis in adenoid cystic carcinoma by SNP genotyping arrays.

Yu Y, Baras AS, Shirasuna K, Frierson HF Jr, Moskaluk CA.

Lab Invest. 2007 May;87(5):430-9. Epub 2007 Mar 19.

45.

Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells.

Pramoonjago P, Baras AS, Moskaluk CA.

Oncogene. 2006 Sep 14;25(41):5626-39. Epub 2006 Apr 24.

PMID:
16636670
46.

DNA microarray analysis of neonatal mouse lung connects regulation of KDR with dexamethasone-induced inhibition of alveolar formation.

Clerch LB, Baras AS, Massaro GD, Hoffman EP, Massaro D.

Am J Physiol Lung Cell Mol Physiol. 2004 Feb;286(2):L411-9. Epub 2003 Nov 7.

Supplemental Content

Loading ...
Support Center